# LFB-Biotechnologies Patents

Matching "LFB-Biotechnolog...' by Owner.



# Contents

Alerts	
"LFB-Biotechnologies"	3
Terms and Conditions	5
General	
Disclaimer of warranty and limitation of liability	5
Copyright	5
Arbitration	5

## Alerts

## "LFB-Biotechnologies"

40 results matching "LFB-Biotechnolo...' by Owner.

Number	Title	Owner
2003282161	Cytokine production-inducing antibody	LFB Biotechnologies
2003283469	Treatment of pathologies which escape the immune response, using optimised antibodies	LFB Biotechnologies
2004261754	Use of ADCC-optimized antibodies for treating weak patients	LFB Biotechnologies
2004283924	Correlation between the fucose content / galactose content ratio of antirhesus-D and anti-HLA-DR antibodies and the ADCC activity	LFB Biotechnologies
2006202914	Anti-idiotypic antibody neutralizing the inhibitor activity of a factor VIII inhibitor antibody	LFB Biotechnologies
2007202060	Anti-D monoclonal antibodies	LFB Biotechnologies
2005315534	Cytotoxic antibody directed against type B lymphoid hematopoietic proliferations	LFB Biotechnologies
2010257417	Anti-D monoclonal antibodies	LFB Biotechnologies
2006328809	Inhibition of the anti-FVIII immune response	Institut National de la Sante et de la Recherche Medicale Etablissement public de recherche a caractere scientifique et technologique ; LFB Biotechnologies
2006328798	Potentiation of apoptosis by monoclonal antibodies	LFB Biotechnologies
2006334552	Method for preparing antibodies selective for activating Fc receptors	LFB Biotechnologies
2007217218	Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII	LFB Biotechnologies
2007266951	Method for the extraction of one or several proteins present in milk	LFB Biotechnologies
2007266952	Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units	LFB Biotechnologies
2007280330	Recombinant Factor VII composition	LFB Biotechnologies
2008214544	Method for extracting a protein from milk	LFB Biotechnologies
2007346741	Monoclonal antibody directed against the human LDL receptor	LFB Biotechnologies Societe Par Actions Simplifiee Unipersonnelle
2007346339	Cell line having a high transcription activity for the production of proteins, in particular therapeutic proteins	LFB Biotechnologies Societe Par Actions Simplifiee Unipersonnelle
2007346300	Method for measuring the concentration of activated factor VII (FVIIa) in a sample	LFB Biotechnologies Societe Par Actions Simplifiee Unipersonnelle
2008240663	Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A	LFB Biotechnologies ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM
2008257271	Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease	LFB Biotechnologies
2008265021	Modified human factor VII/VIIa and pharmaceutical composition containing same	LFB Biotechnologies

www.ipmonitor.com.au 3 of 5

Number	Title	Owner
2008273988	Use of a chromatography substrate for reducing the amount of ADAMTS13 in a solution derived from plasma	LFB Biotechnologies
2008290416	Method for purifying or detecting a target protein	LFB Biotechnologies
2008294610	Method for purifying the factor VIII and the Von Willebrand factor	LFB-Biotechnologies
2007358045	Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII	LFB Biotechnologies
2008332943	G immunoglobulin used against anthrax toxins	LFB-Biotechnologies ; Etat Francais Represente Par Le Delegue General Pour L'Armement
2009235248	Method of detection and/or titration in vitro of an unconventional transmissible agent	LFB-Biotechnologies ; Institut National De La Recherche Agronomique
2009265315	Method for measuring activated factor VII level in a sample	LFB Biotechnologies
2009289107	Stable cell clone expressing a prion	LFB-Biotechnologies ; INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
2009334324	Isolated peptides of rabbit factor VII	LFB Biotechnologies
2010215302	Nucleic acids specifically binding with human factor VII/VIIa and uses thereof	LFB Biotechnologies
2010215303	Means for purifying a coagulation protein, and methods for implementing same	LFB Biotechnologies
2010215304	Means for purifying a protein of blood plasma and methods for implementing same	LFB Biotechnologies
2010224800	Optimized Fc variants	LFB Biotechnologies
2010219518	Anti-Rhesus D monoclonal antibody	LFB-Biotechnologies
2010264369	Factor VII composition	LFB-Biotechnologies
2010277421	Method for purifying active GLA-domain coagulation proteins	LFB Biotechnologies
2010277420	Method for purifying GLA-domain coagulation proteins	LFB Biotechnologies
2012203957	Anti-D monoclonal antibodies	LFB Biotechnologies

www.ipmonitor.com.au 4 of 5

## **Terms and Conditions**

#### General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

### Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information conatined in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

### Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

#### Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms

www.ipmonitor.com.au 5 of 5